

# Jae Ho Jeong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11311559/publications.pdf>

Version: 2024-02-01

23  
papers

565  
citations

840776

11  
h-index

642732

23  
g-index

23  
all docs

23  
docs citations

23  
times ranked

1126  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY. <i>Cancers</i> , 2022, 14, 559.	3.7	10
2	Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis. <i>Cancers</i> , 2022, 14, 1166.	3.7	3
3	Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110030.	3.2	9
4	Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study. <i>European Journal of Cancer</i> , 2021, 144, 341-350.	2.8	5
5	Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review. <i>Cancers</i> , 2021, 13, 1647.	3.7	10
6	Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor-positive, HER2-negative metastatic breast cancer. <i>International Journal of Cancer</i> , 2021, 149, 917-924.	5.1	5
7	Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival. <i>British Journal of Surgery</i> , 2021, 109, 61-70.	0.3	13
8	Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. <i>Lancet Oncology</i> , 2021, 22, 1560-1572.	10.7	118
9	FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095329.	3.2	21
10	Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis. <i>British Journal of Cancer</i> , 2020, 123, 362-368.	6.4	29
11	Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092342.	3.2	14
12	Rivaroxaban versus Low-molecular-weight Heparin for Venous Thromboembolism in Advanced Upper Gastrointestinal Tract and Hepatopancreatobiliary Cancer. <i>In Vivo</i> , 2020, 34, 829-837.	1.3	10
13	Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. <i>Cancer Research and Treatment</i> , 2020, 52, 254-262.	3.0	14
14	Stereotactic body radiation therapy for locally advanced pancreatic cancer. <i>PLoS ONE</i> , 2019, 14, e0214970.	2.5	45
15	Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis. <i>Cancers</i> , 2019, 11, 278.	3.7	31
16	Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores. <i>Investigational New Drugs</i> , 2019, 37, 584-590.	2.6	13
17	Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. <i>Investigational New Drugs</i> , 2018, 36, 732-741.	2.6	87
18	Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin. <i>Investigational New Drugs</i> , 2018, 36, 496-502.	2.6	9

#	ARTICLE	IF	CITATIONS
19	Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer. <i>Cancer Research and Treatment</i> , 2018, 50, 1324-1330.	3.0	21
20	Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 146-155.	5.3	11
21	The role of targeted agents in the adjuvant treatment of colon cancer: a meta-analysis of randomized phase III studies and review. <i>Oncotarget</i> , 2017, 8, 31112-31118.	1.8	10
22	Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients. <i>BMC Cancer</i> , 2016, 16, 900.	2.6	67
23	Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 523-529.	2.3	10